Nudge Therapeutics

Nudge Therapeutics focuses on harnessing the immune system's potential to combat cancer and autoimmune diseases by targeting the cGAS STING pathway. The company is dedicated to discovering small molecules that modulate this pathway, enhancing tumor immunity while mitigating autoimmune responses. Nudge Therapeutics operates in the biopharmaceutical sector, serving clients in the healthcare and pharmaceutical industries. Its business model revolves around drug discovery and development, aiming to create first-in-class therapies that address unmet medical needs. Revenue is generated through partnerships, licensing agreements, and potential commercialization of successful therapies. The company leverages scientific expertise and innovative research to advance its pipeline of therapeutic candidates.

Keywords: immune system, cGAS STING, small molecules, cancer, autoimmune diseases, drug discovery, biopharmaceutical, tumor immunity, therapies, healthcare.